V R Woodart (523888)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me start with a confession: I do not know this company. The figures you handed me are full of contradictions. Price is ₹6.42, yet the 52-week range is ₹40.10 to ₹206. That alone is impossible unless there has been a split, a bonus issue, or a clerical error. Market cap is ₹10 crore, but the latest quarter reports sales of ₹315 crore and profit of ₹3 crore. Three crore rupees quarterly means annual profit of roughly ₹12 crore — so at ₹10 crore market cap the P/E would be under one. Instead I am told P/E is 82.65. Both cannot be true. As Graham said, the first rule is to get the facts; here the facts don't add up. Next, what does look real? ROE is 40.94%, which sounds wonderful, but ROCE is zero and book value is unavailable. A zero return on capital employed with positive net profit tells me earnings may not come from operations. Profit growth of 1000% is exciting only in percentage form; it always comes from a tiny base. With sales growth at zero and a net margin below 1%, this is not a compounding machine. This is a micro-cap in a cyclical tyre and rubber business. There is no dividend, no promoter holding data, no debt/equity figure, and an F-score of just 5 out of 9. The PEG of 0.08 is meaningless because it extrapolates that 1000% profit growth forever. In the real world, that does not happen. I cannot call this an investment. It may be a speculator's ticket or a turnaround story, but only if the data is audited and cleared up. My job is to avoid losing money. Without reliable financials and a durable competitive advantage, I will keep my own counsel and pass. If you want action, watch the next four quarters and demand a proper balance sheet.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer